Drugs / Bevirimat
Bevirimat
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01026727 | Nov 2009 → Jun 2010 | HIV infectious disease | Myrexis Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01097070 | Nov 2008 → Jan 2009 | HIV infectious disease | Myrexis Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00967187 | May 2008 → Nov 2009 | HIV infectious disease | Myrexis Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00511368 | Apr 2006 → Jul 2008 | HIV infectious disease | Myrexis Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bevirimat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00967187 ↗ |
| Known as | MPC-4326 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01026727 ↗ |
| Known as | PA-103001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL404519 ↗ |
| Known as | Yk-fh312 | ChEMBL registry synonym — accepted as the source's own label CHEMBL404519 ↗ |
| Action | Inhibit | “by inhibiting a late step in the Gag processing cascade” NCT00511368 ↗ |
| Modality | Small molecule | — CHEMBL404519 ↗ |
| Route | Oral | “different oral doses administered for two weeks” NCT00511368 ↗ |